Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System
- Conditions
- Trauma-related WoundSurgical Wound LeakSurgical Wound, RecentDehiscence Wound
- Registration Number
- NCT05805046
- Lead Sponsor
- ConvaTec Inc.
- Brief Summary
The main questions the study aims to answer are:
* How much do wounds improve when using the Avelle™ Negative Pressure Wound Therapy System for a maximum of 14 days?
* How safe is the Avelle™ Negative Pressure Wound Therapy System?
- Detailed Description
The goal of this observational study is to gather information about the the Avelle™ Negative Pressure Wound Therapy System in people that have a wound that leaks fluid and is 14 days old or less. The Avelle™ Negative Pressure Wound Therapy (NPWT) System combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump. The Avelle™ NPWT System consists of a disposable single patient use battery powered pump, absorbent wound dressing, and fixation strips.
Participants will:
* be asked questions about their medical history and medications
* asked to allow the wound and surrounding skin to be examined
* be asked to use the Avelle™ Negative Pressure Wound Therapy System for a maximum of 14 days
* be asked to review any issues or concerns with the Avelle™ Negative Pressure Wound Therapy System
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Subject is ≥ 18 years of age.
- Subject is willing and able to take part in the study and provide written informed consent.
- Subject has one target wound which is ≤ 14 days old
- Subject has target wound that is intended to heal by primary intention
- Subject has a target wound which is ≤ 25% of the dressing area as per the Instructions For Use
- Target wound has low to moderate exudate
- Wound is suitable for treatment with Avelle™ NPWT
- Subject is deemed capable and willing to comply with the protocol and product instructions.
- Subject has an existing health condition that would compromise their participation and follow-up in this study such as the ability to understand and follow instructions
- Subject has been treated with another NPWT system during the past 14 days
- Subject, in the opinion of the Investigator, is not clinically suitable for inclusion
- Subject is contraindicated for the Avelle™ NPWT System
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of device-related serious adverse events (SAEs) (all adverse events attributed to the wound and or device will be collected and assessed as non-device related or device related, and serious or non-serious, by the Investigator) Up to 14 days Primary safety outcome
Complete wound healing evidenced by substantially complete epithelialization (>95% by area estimate). Up to 14 days Primary performance outcome
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
The Ohio State University
🇺🇸Columbus, Ohio, United States
The Angel Medical Research Corp
🇺🇸Miami Lakes, Florida, United States
Northwell Health
🇺🇸Lake Success, New York, United States